Dumeaux Lab | Dumeaux Lab
Vanessa Dumeaux

Principal Investigator
CV
Google Scholar
Email
vanessa.dumeauxobfuscate@concordia.ca

Dr. Dumeaux received her doctorate in Pharmacy in 2002 in France. She then obtained her Ph.D. in molecular epidemiology, a joint degree from the University of Tromso (Norway) and the University of Paris-South XI (France). During her PhD, she developed expertise in genomics in the group of Professeur Borresen-Dale at the Norwegian Radium Hospital which was among the pioneers in expression profiling of breast carcinomas in collaboration with groups at Stanford University. Dr Dumeaux co-initiated the post-genomic wing of the Norwegian Women and Cancer cohort to study the systems biology of breast cancer in a population-based context. She has had a long-standing interest in the development of RNA-based biomarker signatures in blood, which can be used to inform on exposure (exposome; eg. organic pollutants) and health status (eg. diagnostics of breast cancer, side-effects of radiotherapy).

During her post-doc, she visited the Department of Applied Mathematics (University of Paris Descartes) and the Laboratory of Bioinformatics and Functional Genomics (Princeton University), and finally moved to Canada in 2009 to continue her research in bioinformatics and genomics at McGill University.

Dr. Dumeaux is currently a Research Scientist at Concordia’s PERFORM Center in Montreal as well as a freelance consultant in data science and systems biology.

Employment, Position:

• 2017-present Senior Scientist, PERFORM Centre, Concordia University

• 2017-present Freelance Consultant, Dumeaux Data Science

• 2014-17 Research Scientist, Breast Cancer Informatics laboratory, McGill University

• 2011-14 Research Scientist, UiT The Arctic University of Norway, visiting McGill University

  • 2013-14 Associate Member,Department of Epidemiology, Biostatistics & Occupational Health
  • 2011-14 Affiliate Assistant Professor, Department of Oncology

• 2006-11 Post-Doctoral & Research Fellow, UiT The Arctic University of Norway, visiting:

  • 2009-11 Goodman Cancer Centre, McGill University
  • 2008-09 Department of Applied Mathematics, University of Paris Descartes
  • 2008 Laboratory of Bioinformatics and Functional Genomics, Princeton University
  • 2006-08 Department of Genetics, The Norwegian Radium Hospital

Education:

2005 PhD Molecular Epidemiology, University of Paris XI and The Arctic University of Norway

2002 MSc Epidemiology and Public Health, University of Bordeaux II, France

2002 Doctor in Pharmacy, University of Poitiers, France

Patents and intellectual property rights:

11/2013 Patent submitted to Patent Cooperation Treaty (PCT/NO2013/050203) Gene expression profile in diagnostics

Funding:

2017-22 Canadian Institutes of Health Research Project grant: DCIS-Precise: A genomics-driven model for predicting DCIS response to radiation (PI: Rakovitch, Hallett)

2015-16 European Research Council: A gene expression test in blood for breast cancer (PI: Lund)

2014-17 Canadian Cancer Society Innovation grant: Interactions between the tumor-microenvironment and the systemic response of breast cancer patients

2009-14 European Research Council: Transcriptomics in cancer epidemiology(PI: Lund)

Papers

Interactions between the tumor and the blood systemic response of breast cancer patients.

The prognostic ease and difficulty of invasive breast carcinoma.

Peripheral blood cells inform on the presence of breast cancer: a population-based case-control study.

High coffee consumption and different brewing methods in relation to postmenopausal endometrial cancer risk in the Norwegian women and cancer study: a population-based prospective study.

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.

Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II.

Using blood gene signatures for assessing effects of exposure to perfluoroalkyl acids (PFAAs) in humans: the NOWAC postgenome study.

Sex hormones and gene expression signatures in peripheral blood from postmenopausal women - the NOWAC postgenome study.

Blood gene expression profiling of breast cancer survivors experiencing fibrosis.

Cigarette smoking and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study.

Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.

The genetics and epigenetics of fatigue.

Deciphering normal blood gene expression variation--The NOWAC postgenome study.

Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition.

Gene expression profiling of peripheral blood cells for early detection of breast cancer.

Towards a more functional concept of causality in cancer research.

Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk.

Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition.

Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.

Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer.

Exploring the human genome with functional maps.

Aneuploidy prediction and tumor classification with heterogeneous hidden conditional random fields.

Systems epidemiology in cancer.

Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study.

Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood.

Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis.

Cohort profile: The Norwegian Women and Cancer Study--NOWAC--Kvinner og kreft.

Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study.

Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy.

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women.

Use of oral contraceptives, alcohol, and risk for invasive breast cancer.

Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study.